190 related articles for article (PubMed ID: 28188407)
1. Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.
Almhanna K; Miron ML; Wright D; Gracian AC; Hubner RA; Van Laethem JL; López CM; Alsina M; Muñoz FL; Bendell J; Firdaus I; Messersmith W; Ye Z; Fasanmade AA; Danaee H; Kalebic T
Invest New Drugs; 2017 Apr; 35(2):235-241. PubMed ID: 28188407
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.
Almhanna K; Wright D; Mercade TM; Van Laethem JL; Gracian AC; Guillen-Ponce C; Faris J; Lopez CM; Hubner RA; Bendell J; Bols A; Feliu J; Starling N; Enzinger P; Mahalingham D; Messersmith W; Yang H; Fasanmade A; Danaee H; Kalebic T
Invest New Drugs; 2017 Oct; 35(5):634-641. PubMed ID: 28527133
[TBL] [Abstract][Full Text] [Related]
3. Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies.
Almhanna K; Kalebic T; Cruz C; Faris JE; Ryan DP; Jung J; Wyant T; Fasanmade AA; Messersmith W; Rodon J
Clin Cancer Res; 2016 Oct; 22(20):5049-5057. PubMed ID: 27178743
[TBL] [Abstract][Full Text] [Related]
4. A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo.
Gallery M; Zhang J; Bradley DP; Brauer P; Cvet D; Estevam J; Danaee H; Greenfield E; Li P; Manfredi M; Loke HK; Rabino C; Stringer B; Williamson M; Wyant T; Yang J; Zhu Q; Abu-Yousif A; Veiby OP
PLoS One; 2018; 13(1):e0191046. PubMed ID: 29370189
[TBL] [Abstract][Full Text] [Related]
5. A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C.
Kim R; Leal AD; Parikh A; Ryan DP; Wang S; Bahamon B; Gupta N; Moss A; Pye J; Miao H; Inguilizian H; Cleary JM
Cancer Chemother Pharmacol; 2023 Apr; 91(4):291-300. PubMed ID: 36738333
[TBL] [Abstract][Full Text] [Related]
6. TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study.
Bang YJ; Takano T; Lin CC; Fasanmade A; Yang H; Danaee H; Asato T; Kalebic T; Wang H; Doi T
Cancer Res Treat; 2018 Apr; 50(2):398-404. PubMed ID: 28494535
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach.
Pant S; Patel M; Kurkjian C; Hemphill B; Flores M; Thompson D; Bendell J
Cancer Invest; 2017 Aug; 35(7):463-472. PubMed ID: 28662341
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.
Propper D; Jones K; Anthoney DA; Mansoor W; Ford D; Eatock M; Agarwal R; Inatani M; Saito T; Abe M; Evans TR
BMC Cancer; 2016 Oct; 16(1):779. PubMed ID: 27724887
[TBL] [Abstract][Full Text] [Related]
9. CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach.
Schmalenberg H; Al-Batran SE; Pauligk C; Zander T; Reichart A; Lindig U; Kleiß M; Müller L; Bolling C; Seufferlein T; Reichardt P; Kullmann F; Eschenburg H; Schmittel A; Egger M; Block A; Goetze TO
J Cancer Res Clin Oncol; 2018 Mar; 144(3):559-569. PubMed ID: 29285668
[TBL] [Abstract][Full Text] [Related]
10. Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies.
Almhanna K; Prithviraj GK; Veiby P; Kalebic T
Pharmacol Ther; 2017 Feb; 170():8-13. PubMed ID: 27765652
[TBL] [Abstract][Full Text] [Related]
11. Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study.
Yamaguchi K; Fujitani K; Nagashima F; Omuro Y; Machida N; Nishina T; Koue T; Tsujimoto M; Maeda K; Satoh T
Gastric Cancer; 2018 Nov; 21(6):1041-1049. PubMed ID: 29508095
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Catabolism of [
Bolleddula J; Shah A; Shadid M; Kamali A; Smith MD; Chowdhury SK
Drug Metab Dispos; 2020 Nov; 48(11):1239-1245. PubMed ID: 32843329
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers.
Wainberg ZA; Soares HP; Patel R; DiCarlo B; Park DJ; Liem A; Wang HJ; Yonemoto L; Martinez D; Laux I; Brennan M; Hecht JR
Cancer Chemother Pharmacol; 2015 Jul; 76(1):61-7. PubMed ID: 25969130
[TBL] [Abstract][Full Text] [Related]
14. Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.
Richards D; Kocs DM; Spira AI; David McCollum A; Diab S; Hecker LI; Cohn A; Zhan F; Asmar L
Eur J Cancer; 2013 Sep; 49(13):2823-31. PubMed ID: 23747051
[TBL] [Abstract][Full Text] [Related]
15. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
[TBL] [Abstract][Full Text] [Related]
16. Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma.
Li J; Yao X; Kortmansky JS; Fischbach NA; Stein S; Deng Y; Zhang Y; Doddamane I; Karimeddini D; Hochster HS; Lacy J
Am J Clin Oncol; 2017 Apr; 40(2):146-151. PubMed ID: 25144267
[TBL] [Abstract][Full Text] [Related]
17. 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium.
Kindler HL; Avadhani A; Wade-Oliver K; Karrison T; Mani S; Vokes EE
Invest New Drugs; 2004 Aug; 22(3):323-7. PubMed ID: 15122080
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.
Mackay HJ; Au HJ; McWhirter E; Alcindor T; Jarvi A; MacAlpine K; Wang L; Wright JJ; Oza AM
Invest New Drugs; 2012 Jun; 30(3):1158-63. PubMed ID: 21400081
[TBL] [Abstract][Full Text] [Related]
19. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
Türeci O; Sahin U; Schulze-Bergkamen H; Zvirbule Z; Lordick F; Koeberle D; Thuss-Patience P; Ettrich T; Arnold D; Bassermann F; Al-Batran SE; Wiechen K; Dhaene K; Maurus D; Gold M; Huber C; Krivoshik A; Arozullah A; Park JW; Schuler M
Ann Oncol; 2019 Sep; 30(9):1487-1495. PubMed ID: 31240302
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.
Bang YJ; Cho JY; Kim YH; Kim JW; Di Bartolomeo M; Ajani JA; Yamaguchi K; Balogh A; Sanchez T; Moehler M
Clin Cancer Res; 2017 Oct; 23(19):5671-5678. PubMed ID: 28655793
[No Abstract] [Full Text] [Related]
[Next] [New Search]
